Pharmacokinetics of Antiepileptic Drug Therapies and Interactions

The pharmacokinetic profile of antiepileptic drugs encompasses absorption, distribution, metabolism and elimination, all of which determine clinical efficacy and safety. Many antiepileptic agents exhibit significant inter-individual variability driven by age, sex, genetic polymorphisms and physiological states such as pregnancy or renal impairment. Enzyme inducers and inhibitors, whether co-prescribed anticonvulsants or dietary constituents, may alter hepatic biotransformation pathways—most notably those mediated by UDP-glucuronosyltransferases and cytochrome P450 enzymes—leading to changes in clearance and steady-state exposure. Advances in population pharmacokinetic and physiologically based pharmacokinetic modelling have refined dose individualisation, while emerging machine-learning techniques have offered predictive tools for therapeutic drug monitoring. A clear understanding of key pharmacokinetic parameters such as peak concentration, area under the concentration–time curve and trough levels remains essential for optimising antiepileptic therapy and minimising drug–drug interactions.

Research from Nature Portfolio

Recent studies have demonstrated that chronic administration of natural products may markedly influence antiepileptic exposure. In rodent models, pre-treatment with date molasses led to significant reductions in peak levetiracetam concentration and total exposure, implicating impaired gastrointestinal absorption as a mechanism for diminished anticonvulsant levels. Separately, a machine-learning framework using non-invasive clinical parameters has been developed to predict individual dose-adjusted lamotrigine concentrations. By applying ensemble regression algorithms to large therapeutic-drug-monitoring datasets, this approach achieved minimal bias and robust precision across the clinically relevant concentration range, offering an accessible tool to aid clinicians in personalised dose selection.

Pharmacokinetics of Antiepileptic Drug Therapies and Interactions publication trend

The graph below shows the total number of articles in pharmacokinetics of antiepileptic drug therapies and interactions across all publications each year (not limited to Nature Index journals).

Technical terms

Area under the concentration–time curve (AUC): A measure of overall drug exposure over time.

Peak plasma concentration (Cmax): The highest concentration attained after dosing.

Physiologically based pharmacokinetic (PBPK) modelling: A mechanistic modelling approach integrating physiology and drug properties to predict pharmacokinetics in various populations.

Clearance (CL/F): The volume of plasma from which drug is completely removed per unit time, adjusted for bioavailability.

Volume of distribution (V/F): A theoretical volume that relates the amount of drug in the body to plasma concentration, adjusted for bioavailability.

Therapeutic drug monitoring (TDM): Measurement of drug concentrations in biological fluids to guide individualised dosing.

References

1. PBPK Modeling of Lamotrigine and Efavirenz during Pregnancy: Implications for Personalized Dosing and Drug-Drug Interaction Management. Pharmaceutics (2024).
2. Comparison of pharmacokinetics and safety between CE-fosphenytoin sodium, fosphenytoin sodium, and phenytoin sodium after intravenous and intramuscular administration in healthy volunteers. Frontiers in Pharmacology (2023).
3. Physiologically Based Pharmacokinetic Modeling to Predict Lamotrigine Exposure in Special Populations to Facilitate Therapeutic Drug Monitoring and Guide Dosing Regimens. Pharmaceuticals (2025).
4. Effect of date molasses on levetiracetam pharmacokinetics in healthy rats. Scientific Reports (2023).
5. A machine learning approach to personalized dose adjustment of lamotrigine using noninvasive clinical parameters. Scientific Reports (2021).